Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Peng, M ^a   Ball Kell, S M ^a   Franks, R R ^a   Xie, H ^a   Tyner, A L ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

BRK; ERBB2; PTK6; Sik; STAT3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 6; RAS PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LONG TERMINAL REPEAT; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; TRANSGENIC MOUSE;

ANIMALIA; MOUSE MAMMARY TUMOR VIRUS; MUS; MUS MUSCULUS;

EID: 84890150360     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.43     Document Type: Article

References (59)

1. ACS. Cancer Facts & Figures 2013. American Cancer Society: Atlanta, GA, USA, 2013.
2. Serfas MS, Tyner AL. Brk Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncol Res 2003; 13: 409-419. (Pubitemid 38166373)
3. Harvey AJ, Crompton MR. The Brk protein tyrosine kinase as a therapeutic target in cancer: opportunities and challenges. Anticancer Drugs 2004; 15: 107-111. (Pubitemid 38316742)
4. Brauer PM, Tyner AL. Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. Biochim et biophysic acta 2010; 1806: 66-73.
5. Ostrander JH, Daniel AR, Lange CA. Brk/PTK6 signaling in normal and cancer cell models. Curr Opin Pharmacol 2010; 10: 662-669.
6. Zheng Y, Tyner AL. Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer. Eur J Clin Invest 2013; 43: 397-404.
7. Mitchell PJ, Barker KT, Martindale JE, Kamalati T, Lowe PN, Page MJ et al. Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene 1994; 9: 2383-2390. (Pubitemid 24228691)
8. Harvey AJ, Pennington CJ, Porter S, Burmi RS, Edwards DR, Court W et al. Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage. Am J Pathol 2009; 175: 1226-1234.
9. Ostrander JH, Daniel AR, Lofgren K, Kleer CG, Lange CA. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res 2007; 67: 4199-4209. (Pubitemid 46815066)
10. Barker KT, Jackson LE, Crompton MR. BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene 1997; 15: 799-805. (Pubitemid 27390132)
11. Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z et al. PTK6 regulates IGF-1- induced anchorage-independent survival. PLoS One 2010; 5: e11729.
12. Born M, Quintanilla-Fend L, Braselmann H, Reich U, Richter M, Hutzler P et al. Simultaneous over-expression of the Her2/neu and PTK6 tyrosine kinases in archival invasive ductal breast carcinomas. J Pathol 2005; 205: 592-596. (Pubitemid 40514832)
13. Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, Braselmann H et al. (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer 2007; 96: 801-807. (Pubitemid 46376621)
14. Xiang B, Chatti K, Qiu H, Lakshmi B, Krasnitz A, Hicks J et al. Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc Natl Acad Sci USA 2008; 105: 12463-12468.
15. Ludyga N, Anastasov N, Rosemann M, Seiler J, Lohmann N, Braselmann H et al. Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells. Mol Cancer Res 2013; 11: 381-392.
16. Vasioukhin V, Serfas MS, Siyanova EY, Polonskaia M, Costigan VJ, Liu B et al. A novel intracellular epithelial cell tyrosine kinase is expressed in the skin and gastrointestinal tract. Oncogene 1995; 10: 349-357.
17. Haegebarth A, Bie W, Yang R, Crawford SE, Vasioukhin V, Fuchs E et al. Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine. Mol Cell Biol 2006; 26: 4949-4957. (Pubitemid 43955811)
18. Vasioukhin V, Tyner AL. A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation. Proc Natl Acad Sci USA 1997; 94: 14477-14482. (Pubitemid 28041399)
19. Wang TC, Jee SH, Tsai TF, Huang YL, Tsai WL, Chen RH. Role of breast tumour kinase in the in vitro differentiation of HaCaT cells. Br J Dermatol 2005; 153: 282-289. (Pubitemid 41228423)
20. Liu L, Gao Y, Qiu H, Miller WT, Poli V, Reich NC. Identification of STAT3 as a specific substrate of breast tumor kinase. Oncogene 2006; 25: 4904-4912. (Pubitemid 44201181)
21. Gao Y, Cimica V, Reich NC. Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3. J J Biol Chem 2012; 287: 20904-20912.
22. Llor X, Serfas MS, Bie W, Vasioukhin V, Polonskaia M, Derry J et al. BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res 1999; 5: 1767-1777. (Pubitemid 29334458)
23. Matsui Y, Halter SA, Holt JT, Hogan BL, Coffey RJ. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 1990; 61: 1147-1155.
24. Hennighausen L. Mouse models for breast cancer. Breast Cancer Res 2000; 2: 2-7. (Pubitemid 32223553)
25. Sinn E, Muller W, Pattengale P, Tepler R, Wallace R, Leder P. Coexpression of MMTV/ v-Ha-ras and MMTV-/c-myc genes in transgenic mice. Cell 1987; 48: 465-475.
26. Bouchard L, Lamarre PJ, Tremblay PJ, Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV-/c-neu oncogene. Cell 1989; 57: 931-936. (Pubitemid 19168373)
27. Pierce DF, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF et al. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-b. Genes Dev 1993; 7: 2308-2317. (Pubitemid 24003235)
28. Haricharan S, Li Y. STAT signaling in mammary gland differentiation, cell survival and tumorigenesis. Mol Cell Endocrinol (e-pub ahead of print 28 March 2013; doi:10.1016/jmce.2013.03.014).
29. Gierut JJ, Mathur PS, Bie W, Han J, Tyner AL. Targeting protein tyrosine kinase 6 enhances apoptosis of colon cancer cells following DNA damage. Mol Cancer Therap 2012; 11: 2311-2320.
30. Ludyga N, Anastasov N, Gonzalez-Vasconcellos I, Ram M, Hofler H, Aubele M. Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer. Mol Biosyst 2011; 7: 1603-1612.
31. Ai M, Liang K, Lu Y, Qiu S, Fan Z. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition. Cancer Biol Therapy 2013; 14: 237-245.
32. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007; 7: 389-397. (Pubitemid 46652484)
33. Lofgren KA, Ostrander JH, Housa D, Hubbard GK, Locatelli A, Bliss RL et al. Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK. Breast Cancer Res 2011; 13: R89.
34. Kamalati T, Jolin HE, Mitchell PJ, Barker KT, Jackson LE, Dean CJ et al. Brk a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem 1996; 271: 30956-30963. (Pubitemid 26404123)
35. Kamalati T, Jolin HE, Fry MJ, Crompton MR. Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene 2000; 19: 5471-5476. (Pubitemid 32000914)
36. Chen HY, Shen CH, Tsai YT, Lin FC, Huang YP, Chen RH. Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol 2004; 24: 10558-10572.
37. Ikeda O, Miyasaka Y, Sekine Y, Mizushima A, Muromoto R, Nanbo A et al. STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation. Biochem Biophys Res Commun 2009; 384: 71-75.
38. Ikeda O, Sekine Y, Mizushima A, Nakasuji M, Miyasaka Y, Yamamoto C et al. Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells. J Biol Chem 2010; 285: 38093-38103.
39. Weaver AM, Silva CM. Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. Breast Cancer Res 2007; 9: R79.
40. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest 2011; 121: 2723-2735.
41. Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 2010; 70: 2445-2454.
42. Gierut J, Zheng Y, Bie W, Carroll RE, Ball-Kell S, Haegebarth A et al. Disruption of the mouse protein tyrosine kinase 6 gene prevents STAT3 activation and confers resistance to azoxymethane. Gastroenterology 2011; 141: 1371-80 e2.
43. Haegebarth A, Heap D, Bie W, Derry JJ, Richard S, Tyner AL. The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2. J Biol Chem 2004; 279: 54398-54404. (Pubitemid 40053179)
44. Haegebarth A, Nunez R, Tyner AL. The intracellular tyrosine kinase Brk sensitizes non-transformed cells to inducers of apoptosis. Cell Cycle 2005; 4: 1239-1246. (Pubitemid 41365396)
45. Haegebarth A, Perekatt AO, Bie W, Gierut JJ, Tyner AL. Induction of protein tyrosine kinase 6 in mouse intestinal crypt epithelial cells promotes DNA damage-induced apoptosis. Gastroenterology 2009; 137: 945-954.
46. Derry JJ, Prins GS, Ray V, Tyner AL. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene 2003; 22: 4212-4220. (Pubitemid 36876242)
47. Brauer PM, Zheng Y, Wang L, Tyner AL. Cytoplasmic retention of protein tyrosine kinase 6 promotes growth of prostate tumor cells. Cell Cycle 2010; 9: 4190-4199.
48. Ie Kim H, Lee ST. Oncogenic functions of PTK6 are enhanced by its targeting to plasma membrane but abolished by its targeting to nucleus. J Biochem 2009; 146: 133-139.
49. Palka-Hamblin HL, Gierut JJ, Bie W, Brauer PM, Zheng Y, Asara JM et al. Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6. J Cell Sci 2010; 123(Pt 2): 236-245.
50. Zheng Y, Gierut J, Wang Z, Miao J, Asara JM, Tyner AL. Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. Oncogene 2012; 32: 4304-4312.
51. Zheng Y, Wang Z, Bie W, Brauer PM, Perez-White BE, Li J et al. PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer. Cancer Res 2013; 73: 5426-5437.
52. Zheng Y, Peng M, Wang Z, Asara JM, Tyner AL. Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol 2010; 30: 4280-4292.
53. Zheng Y, Asara JM, Tyner AL. Protein-tyrosine Kinase 6 promotes peripheral adhesion complex formation and cell migration by phosphorylating p130 CRKassociated substrate. J Biol Chem 2012; 287: 148-158.
54. Regan Anderson TM, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ et al. Breast tumor kinase (Brk/PTK6) Is a mediator of hypoxia-associated breast cancer progression. Cancer Res 2013; 73: 5810-5820.
55. Harvey AJ, Crompton MR. Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene 2003; 22: 5006-5010. (Pubitemid 37026399)
56. Zhao C, Yasui K, Lee CJ, Kurioka H, Hosokawa Y, Oka T et al. Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 2003; 98: 18-23. (Pubitemid 36741120)
57. Ma S, Bao JY, Kwan PS, Chan YP, Tong CM, Fu L et al. Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. Gastroenterology 2012; 143: 675-86 e1-12.
58. Liu XK, Zhang XR, Zhong Q, Li MZ, Liu ZM, Lin ZR et al. Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma. J Transl Med 2013; 11: 59.
59. Rasband WS. ImageJ. U S National Institutes of Health: Bethesda, MA, USA, 1997-2011; http://imagej.nih.gov/ij/.